Pharmacyclics has received clearance from the Food and Drug Administrationto begin phase-one clinical trials to investigate the safety andutility of its gadolinium-texaphyrin agent for MRI contrast andradiation therapy applications.
Pharmacyclics has received clearance from the Food and Drug Administrationto begin phase-one clinical trials to investigate the safety andutility of its gadolinium-texaphyrin agent for MRI contrast andradiation therapy applications.
Gadolinium-texaphyrin is an expanded porphyrin compound thatdiffers from current extracellular contrast media in that it hasbeen shown to enter cancer cells selectively, according to theSunnyvale, CA, company.
Gadolinium-texaphyrin is the second Pharmacyclics MRI agentto enter human clinical studies and the first agent based on thecompany's texaphyrin technology. Another Pharmacyclics agent,Gadolite, is well into phase-three clinical studies, the companysaid.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.